glecaprevir: Clinical Trials

22 trials of glecaprevir, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

21 completed, 1 unknown. 22 Phase 3, 6 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 322Completed 21, Unknown 1
Phase 26Completed 6

Follow glecaprevir: new trials by email Literature Review of glecaprevir trials Research Report on glecaprevir

Trials (filtered) newest first · largest first

All 22 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Glecaprevir/Pibrentasvir for the Treatment of PTSD
Glecaprevir / Pibrentasvir Pill - PTSD
Phase 2 / Phase 3CompletedWhite River Junction Veterans Affairs Medical Center102023-04-012024-08-29
Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)
Glecaprevir/Pibrentasvir (GLE/PIB) - Hepatitis C Virus (HCV)
Phase 3CompletedAbbVie2862021-08-242025-04-06
Utilization of Hepatitis C Positive Kidneys in Negative Recipients
Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET] - Kidney Transplant, Hepatitis C
Phase 2 / Phase 3CompletedOhio State University542019-03-222023-09-13
Transplantation Using Hepatitis C Positive Donors, A Safety Trial
Glecaprevir 300 MG / Pibrentasvir 120 MG Oral Tablet, Ezetimibe 10Mg Oral Tablet, Ex Vivo Lung Perfusion - Lung Transplant Infection, Heart Transplant Infection
Phase 3UnknownJordan Feld402018-08-062019-07-12
A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection
Glecaprevir/Pibrentasvir - Hepatitis C Virus (HCV)
Phase 3CompletedAbbVie1002018-06-062020-03-17
Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients
glecaprevir (300mg)/pibrentasvir (120mg) - Hepatitis C, Chronic
Phase 3CompletedKirby Institute3802017-08-212019-12-11
A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis
Glecaprevir/Pibrentasvir - Hepatitis C Virus (HCV)
Phase 3CompletedAbbVie3432017-04-282020-07-13
Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects
Glecaprevir/Pibrentasvir (G/P) 300mg/120mg, Ribavirin 200Mg Tablet - Hepatitis C, HCV
Phase 3CompletedUniversity of Florida1772017-04-202020-02-26
A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection
Glecaprevir/Pibrentasvir Adult Formulation, Glecaprevir + Pibrentasvir Pediatric Formulation - Hepatitis C Virus (HCV)
Phase 2 / Phase 3CompletedAbbVie1292017-03-202023-05-09
A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)
ABT-493 coformulated with ABT-530 - Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection
Phase 3CompletedAbbVie1532016-05-172021-07-13
A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2)
glecaprevir/pibrentasvir - Chronic Hepatitis C, HCV
Phase 3CompletedAbbVie1002016-04-222021-07-13
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection
ABT-493/ABT-530, sofosbuvir (SOF), ribavirin (RBV) - Chronic Hepatitis C Virus, Hepatitis C Virus
Phase 3CompletedAbbVie1362016-04-082021-07-16
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection
ABT-493/ABT-530, OBV/PTV/r - Chronic Hepatitis C Virus, Hepatitis C Virus
Phase 3CompletedAbbVie2952016-02-222021-07-16
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis
ABT-493/ABT-530 - Hepatitis C Virus Infection, Chronic Hepatitis C
Phase 3CompletedAbbVie1462015-12-072021-07-13
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
ABT-493/ABT-530, Sofosbuvir, Daclatasvir - Chronic Hepatitis C, Hepatitis C Virus
Phase 3CompletedAbbVie5062015-12-012021-07-30
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection
ABT-493/ABT-530 - Chronic Hepatitis C Virus (HCV) Infection
Phase 3CompletedAbbVie1042015-12-012017-10-16
The Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4)
ABT-493/ABT-530 - Hepatitis C Virus
Phase 3CompletedAbbVie1212015-11-012021-07-13
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection
ABT-493/ABT-530, Placebo for ABT-493/ABT-530 - Chronic Hepatitis C Virus (HCV) Infection
Phase 3CompletedAbbVie3042015-11-012021-07-16
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection
ABT-493/ABT-530 - Chronic Hepatitis C, Hepatitis C Virus
Phase 3CompletedAbbVie7032015-10-012021-07-13
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
ABT-493, ABT-530 - Hepatitis C
Phase 2 / Phase 3CompletedAbbVie3842015-06-222020-09-21

Showing 20 of 22. Sign in to see all of them.

Conditions studied

Hepatitis C (21)  ·  Hepatitis C, Chronic (17)  ·  Fibrosis (3)  ·  Infections (3)  ·  Acquired Immunodeficiency Syndrome (1)  ·  Renal Insufficiency (1)  ·  Stress Disorders, Post-Traumatic (1)

Sponsors

AbbVie (17)  ·  Jordan Feld (1)  ·  Kirby Institute (1)  ·  Ohio State University (1)  ·  University of Florida (1)  ·  White River Junction Veterans Affairs Medical Center (1)

Countries

United States (8)  ·  Canada (6)  ·  Germany (4)  ·  United Kingdom (4)  ·  Australia (3)  ·  France (3)  ·  Puerto Rico (3)  ·  Spain (3)  ·  Belgium (2)  ·  Italy (2)  ·  New Zealand (2)  ·  Russia (2)  ·  Austria (1)  ·  Brazil (1)  ·  Bulgaria (1)

Top investigators

Bradley V Watts, MD, MPH (1)  ·  David R Nelson, MD (1)  ·  Gregory Dore (1)  ·  Jordan Feld, MD, MPH (1)  ·  Reem Daloul, MD (1)  ·  Susan Rhee, MD (1)

Results publications

PMID 30977945, PMID 30012435, PMID 30923816, PMID 31568620, PMID 30529905, PMID 30868245, PMID 29180522, PMID 35174470, PMID 27456384, PMID 28128852, PMID 28865152, PMID 28941361, PMID 28951228, PMID 29020583, PMID 31254392, PMID 31401140, PMID 31655134, PMID 31682879, PMID 32389183, PMID 32949786, PMID 33811356, PMID 34023351, PMID 35220658, PMID 41297677, PMID 42189498, PMID 42340583

NIH funding

2015 (10), 2016 (2), 2014 (1)